Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,356 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,709 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,403)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00027326 | Collection of Blood and Urine From Patients Undergoing Radiation Therapy | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00068003 | Harvesting Cells for Experimental Cancer Treatments | enrolling by invitation | — | 7,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02146170 | Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors | recruiting | — | 2,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02682667 | Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols | recruiting | — | 500 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03030404 | Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer | completed | — | 733 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03076554 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03412877 | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | recruiting | Phase 2 | 285 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03623464 | RCT of Mobile Apps & FitBit v. Usual Care | suspended | N/A | 107 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | terminated | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 28, 2026 | clinicaltrials |
| NCT03976323 | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | completed | Phase 3 | 1,003 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT04071223 | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | active not recruiting | Phase 2 | 98 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04405401 | Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer(SUPPRESS-NSCLC) | terminated | Phase 2 | 52 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04487080 | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer(MARIPOSA) | active not recruiting | Phase 3 | 1,074 | Janssen Research & Development, LLCINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT04644770 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | active not recruiting | Phase 1 | 144 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04645160 | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04988295 | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure(MARIPOSA-2) | active not recruiting | Phase 3 | 776 | Janssen Research & Development, LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | recruiting | Phase 3 | 360 | National Cancer Institute (NCI)NIH | 3 | Sep 28, 2026 | clinicaltrials |
| NCT05388669 | A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer(PALOMA-3) | active not recruiting | Phase 3 | 418 | Janssen Research & Development, LLCINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT05498428 | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer(PALOMA-2) | recruiting | Phase 2 | 520 | Janssen Research & Development, LLCINDUSTRY | 12 | Sep 28, 2026 | clinicaltrials |
| NCT05540925 | Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma | completed | — | 3,650 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05562830 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | recruiting | Phase 1 / Phase 2 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | recruiting | Phase 2 | 2,900 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT05642195 | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer | suspended | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05712356 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors(BOLSTER) | completed | Phase 2 | 66 | Lisata Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05753722 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | completed | Phase 1 | 79 | Incendia TherapeuticsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05867251 | Study of AVZO-021 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 430 | Avenzo Therapeutics, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT05880160 | Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction(HER-SAFE) | completed | N/A | 90 | University College, LondonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05956093 | 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study(FAST HOC) | active not recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05965999 | Lucid Registry Study(Lucid Registry) | recruiting | — | 8,000 | Lucid Diagnostics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06031805 | PRostate Olaparib Real World Evidence Study(PROWESs) | active not recruiting | — | 159 | AstraZenecaINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06075953 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | recruiting | Phase 2 | 400 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 433 | BeOne MedicinesINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06331299 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer(UTOPIA) | active not recruiting | Phase 3 | 99 | UroGen Pharma Ltd.INDUSTRY | 7 | Sep 28, 2026 | clinicaltrials |
| NCT06388967 | Pancreatic Cancer Detection Consortium(PCDC) | recruiting | — | 2,000 | City of Hope Medical CenterOTHER | 3 | Sep 28, 2026 | clinicaltrials |
| NCT06406465 | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06472817 | Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men | enrolling by invitation | — | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06487481 | Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma | recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 238 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer(RAINFOL-02) | active not recruiting | Phase 3 | 584 | GenmabINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | recruiting | Phase 3 | 680 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 28, 2026 | clinicaltrials |
| NCT06694454 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | suspended | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06726161 | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC(GPC3) | recruiting | Phase 1 / Phase 2 | 590 | RayzeBio, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06770582 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | recruiting | Phase 2 | 160 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT06833073 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | recruiting | Phase 2 | 308 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 28, 2026 | clinicaltrials |
| NCT06833658 | Effects of Aromatherapy With Essential Oils on Anxiety and Depression in Perioperative Patients With Pancreatic Cancer | completed | N/A | 156 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06919965 | A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer(MoonRISe-3) | recruiting | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT06931717 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy(ARCH) | recruiting | Phase 3 | 390 | ETOP IBCSG Partners FoundationNETWORK | 9 | Sep 28, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials